Reviva Q2 2024 net loss $7.9M; cash $6.2M; OLE topline data expected Q4 2024

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss of $7.9M ($0.26/sh) vs $11.7M ($0.52/sh) in Q2 2023; six-month loss $15.3M ($0.51/sh).
Cash $6.2M at June 30, 2024, down from $23.4M at Dec 31, 2023.
Topline data from 1-year OLE trial in schizophrenia expected Q4 2024; registrational RECOVER-2 trial to start Q3 2024.
U.S. patent granted for brilaroxazine in IPF; European patent for pulmonary hypertension; both received Orphan Drug Designation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.